EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways

Mingjie Liu, Yanxia Li, Chengxue Qin, Lingling Wang, Meiqi Guo, Yi Wang, Qian Zhou, Zhida Shi, Weimin Hao, Yuan Li, Baobing Zhao

Pharmaceutical Science Advances · 2026-12 · 4 · 100121

DOI: 10.1016/j.pscia.2026.100121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Mingjie Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong University, Jinan, Shandong, 250…. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Programme, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Fufang Huangbo FormulaMyeloproliferative neoplasmsNF-κBSTAT3Senescencep53/p21

Autor:innen und Institutionen

  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong University, Jinan, Shandong, 250012, China.
  • Key Lab of Chemical Biology (MOE), Shandong University, Jinan, Shandong, 250012, China.
  • NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Pharmacology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
  • Research Center for Traditional Chinese Medicine and Clinical Pharmacy, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, Shandong, 250012, China.
  • Department of Spine Surgery, Heze Municipal Hospital, 2888 Caozhou Road, Heze, Shandong, 274031, China.

Förderung

  • Key Programme
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Liu, M., Li, Y., Qin, C., Wang, L., Guo, M., Wang, Y., Zhou, Q., Shi, Z., Hao, W., Li, Y., & Zhao, B. (2026). Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. Pharmaceutical Science Advances, 4, 100121. https://doi.org/10.1016/j.pscia.2026.100121

Vancouver

Liu M, Li Y, Qin C, Wang L, Guo M, Wang Y, et al. Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. Pharmaceutical Science Advances. 2026;4:100121. doi:10.1016/j.pscia.2026.100121

BibTeX
@article{Liu2026,
  author = {Liu, Mingjie and Li, Yanxia and Qin, Chengxue and Wang, Lingling and Guo, Meiqi and Wang, Yi and Zhou, Qian and Shi, Zhida and Hao, Weimin and Li, Yuan and Zhao, Baobing},
  title = {Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways},
  journal = {Pharmaceutical Science Advances},
  year = {2026},
  volume = {4},
  pages = {100121},
  doi = {10.1016/j.pscia.2026.100121}
}
Kostenlos starten →